[1] Jankowska EA, Malyszko J, Ardehali H, et al.Iron status in patients with chronic heart failure[J]. Eur Heart J,2013,34:827-834. [2] Ponikowski P, Veldhuisen DJ, Comin-Colet J,et al.Benefificial effects of long-term intravenousiron therapy with ferric carboxymaltose in patients with symptomatic heart failureand iron defificiency[J]. Eur Heart J,2015,(36):657-668. [3] Filippatos G,Farmakis D,Colet JC.Intravenous ferric carboxymaltose in iron-defificient chronic heart failure patients with and without anaemia: a subanalysis of theFAIR-HF trial[J]. Eur J Heart Fail ,2013,(15):1267-1276. [4] 中华医学会心血管病学分会心力衰竭学组,2018年中国心力衰竭诊断和治疗指南[J].中华心血管病杂志,2018,46(10);760-789. [5] AlcaideAldeano A, Garay A, Alcoberro L, et al.Iron deficiency:impact on functional capacity and quality of life in heart failure with preserved ejection fraction[J].J Clin Med,2020,9(4):1199. [6] 符浩,聂绍平,白融.缺铁对射血分数保留的慢性心力衰竭患者预后的影响[J]中华心血管病杂志,2021,49,(5):479-486. [7] 陈文彬,潘祥林.诊断学[M].第7版.北京:人民卫生出版社,2008,390-391. [8] 许永健,田庄.静脉补铁治疗在慢性心力衰竭合并铁缺乏患者中的应用[J].临床药物治疗杂志,2021,19(8):1-6. [9] Ponikowski P,van Veldhuisen DJ,Comin-Colet J,et al. Benefificial effects of long-term intravenousiron therapy with ferric carboxymaltose in patients with symptomatic heart failureand iron defificiency[J]. Eur Heart J,2015,36:657-668. [10] Klip IT,CominColet J,Voors AA,et al.Iron deficiency in chronic heart failure: an international pooled analysis[J].Am Heart J,2013,165(4):575-582. [11] Jankowska EA,Tkaczyszyn M,Suchocki T.Effects of intravenous iron therapy in iron-defificient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail[J]. 2016. |